SUDDEN DEATH IN HYPERTROPHIC CARDIOMYOPATHY: SEARCH FOR NEW RISK FACTORS

Regardless the developed algorithms for risk stratification in sudden cardiac death (SCD) among patients with hypertrophy cardiomyopathy (HCM) there are SCD cases with no common risk factors. The issue for prediction of SCD in this pathology does not lose its importance.

Aim. To study the risk factors for SCD in HCM patients.

Material and methods. During 14 years, 198 HCM patients studied (mean age — 60,0±13,8 y.o., 105 males) with ECG, EchoCG, Holter ECG, veloergometry done. During 14 years, 15 died. There was 7 SCD cases with 2 successful resuscitations.

Results. In HCM patients there was relation of SCD with the following clinical and instrumental parameters: age (r=-0,19, p=0,015), syncopes in anamnesis (r=0,17, p=0,03), high flow velocity in outflow tract of the left ventricle (LV) in exertion (Ex) (VmaxLVOT) (r=0,3, p=0,04), low Ex tolerance (r=-0,34, p=0,009), abnormal Ex response of blood pressure (ABPR) (r=0,36, p=0,00001), high minimal heart rate (HR) on Holter ECG (r=0,26, p=0,01). Applying the binary logistic regression with inclusion of the most significant predictors, the model was formulated for SCD prediction in HCM patients: SCD=22,28хABPR-6,9хEx Duration+12,5хVmaxLVOT+0,32хMinHR-0,4478хAge-14,7 If the result of equation more than 0 — the patient has high risk of SCD. In negative — SCD risk is minimal. Value of χ2 for the proposed equation is 19,3 (p=0,002).

Conclusion. Regardless the common (age, syncopes, severity of LVOT obstruction, ABPR in Ex) there are additional SCD risk factors in HCM patients: low Ex tolerance and high minimal HR on Holter ECG. the mathematic model proposed, making to, based on the age of patient and presence of ABPR in Ex, Ex tolerance, maximal flow velocity in LVOT in Ex, as minimal HR by Holter ECG, to reveal patients with high risk of SCD.

1. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-16.

2. Gersh B.J., Maron B.J., Bonow R.O. et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation – 2011 – Vol.124 – P. 783 - 831.

3. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal. 2014. P. 2733-2779.

4. O’Mahony C, Jichi F, Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20.

5. Dubourg O, Charron P, Sirol M et al. Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016. Presse Med. 2016 Oct;45(10):903-910.

6. Priori SG, Blomström-Lundqvist C, Mazzanti A et all. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal doi:10.1093/eurheartj/ehv316.

7. Harmon KG, Asif IM, Maleszewski JJ, Incidence and Etiology of Sudden Cardiac Arrest and Death in High School Athletes in the United States. Mayo Clin Proc. 2016 Nov;91(11):1493-1502.

8. Maron BJ, Doerer JJ, Haas TS, et al: Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the U.S., 1980-2006. Circulation 119:1085, 2009.

9. Komissarova SM, Melnikova OP, Gevorkyan TT. et al. Prediction of sudden cardiac death at hypertrophic cardiomyopathy: high risk patients identification. Journal Heart Failure. 2013 T. 14, №6(80). P. 322-328. (Комиссарова С.М., Мельникова О.П., Геворкян Т.Т. с соавт. Прогнозирование внезапной сердечной смерти при гипертрофической кардиомиопатии: идентификация пациентов высокого риска. Журнал сердечная недостаточность. 2013. Т. 14. № 6(80). С. 322-328).

10. Emoto R, Yokota Y, Miki T. et al. Prognosis of hypertrophic cardiomyopathy: echocardiographic and postmortem histopathologic study of 30 patients. J Cardiol. 1988 Sep;18(3):695-703.

11. Belenkov YN., Privalova EV., Kaplunova VY. Hypertrophic cardiomyopathy: guideline for physicians. –M.: GEOTAR-Media, 2011.-392 p. (Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. Гипертрофическая кардиомиопатия: руководство для врачей. – М.: ГЭОТАР-Медиа, 2011. – 392 с.: ил.).

12. Peteiro J, Bouzas-Mosquera A, Fernandez X et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012 Feb;25(2):182-9.

13. El-Saiedi SA, Seliem ZS, Esmail RI. Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients. Cardiol Young. 2013 Jul 29:1-7.

14. Kawasaki T, Sakai C, Harimoto K, et al. Holter monitoring and long-term prognosis in hypertrophic cardiomyopathy. Cardiology. 2012;122(1):44-54.